Global developmental delay
|
0.100 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
Poor school performance
|
0.100 |
GeneticVariation
|
phenotype |
CLINVAR |
|
|
|
leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
These results suggest that ASH2L plays a role in hematopoiesis and is associated with some special kinds of leukemia.
|
11466562 |
2001 |
Childhood Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
These results suggest that ASH2L plays a role in hematopoiesis and is associated with some special kinds of leukemia.
|
11466562 |
2001 |
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Ash2 was expressed in 84.4% of hepatocellular carcinomas (38/45) and correlated directly with H3K4diMe modification (correlation coefficient r = 0.53) and LSD1 expression (r = 0.35).
|
19896696 |
2010 |
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Therefore, we investigated dimethylation of histone H3 at lysine 4 (H3K4diMe) and H3K4 methylating (Ash2 complex) and demethylating enzymes (LSD1) in carcinomas of the hepatic and gastrointestinal tract.
|
19896696 |
2010 |
Congenital Heart Defects
|
0.010 |
Biomarker
|
group |
BEFREE |
We provide examples of how several cardiac TFs, such as Nkx2.5, WHSC1, Tbx5, and Tbx1, which are associated with developmental and congenital heart defects, are required for the recruitment of histone modifiers, such as Jarid2, p300, and Ash2l, and components of ATP-dependent remodeling enzymes like Brg1, Baf60c, and Baf180.
|
22194017 |
2012 |
Age at menopause
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways.
|
22267201 |
2012 |
Age at menopause
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways.
|
22267201 |
2012 |
Age at menopause
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
A genome-wide association study of early menopause and the combined impact of identified variants.
|
23307926 |
2013 |
Age at menopause
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A genome-wide association study of early menopause and the combined impact of identified variants.
|
23307926 |
2013 |
Schizophrenia
|
0.200 |
Biomarker
|
disease |
RGD |
Prenatal MAM administration affects histone H3 methylation in postnatal life in the rat medial prefrontal cortex.
|
23932495 |
2014 |
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study established that ASH2L enhances ERα expression as a coactivator of GATA3 in breast cancers.
|
25258321 |
2014 |
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that increased ASH2L expression, which can result from gene amplification, is often correlated with increased ERα expression in both breast cancer cell lines and primary breast cancers.
|
25258321 |
2014 |
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Depletion of ASH2 ameliorated cancer cell migration and invasion in an MMP9-dependent manner.
|
25746000 |
2015 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Depletion of ASH2 ameliorated cancer cell migration and invasion in an MMP9-dependent manner.
|
25746000 |
2015 |
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Depletion of ASH2 ameliorated cancer cell migration and invasion in an MMP9-dependent manner.
|
25746000 |
2015 |
Age at menopause
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair.
|
26414677 |
2015 |
leukemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
ASH2L protein levels in primary leukemia patient samples have not yet been defined.
|
28185526 |
2017 |
Childhood Leukemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
ASH2L protein levels in primary leukemia patient samples have not yet been defined.
|
28185526 |
2017 |
MIXED LINEAGE LEUKEMIA
|
0.020 |
Biomarker
|
disease |
BEFREE |
ASH2L encodes a trithorax group protein that is a core component of all characterized mammalian histone H3K4 methyltransferase complexes, including mixed lineage leukemia (MLL) complexes.
|
28185526 |
2017 |
Acute monocytic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Together, these results indicate that a lower level of ASH2L protein is beneficial to AML patients.
|
28185526 |
2017 |
Leukemia, Myelocytic, Acute
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Together, these results indicate that a lower level of ASH2L protein is beneficial to AML patients.
|
28185526 |
2017 |
leukemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The histone H3 lysine 4 (H3K4) presenter WDR5 forms protein complexes with H3K4 methyltransferases MLL1-MLL4 and binding partner proteins including RBBP5, ASH2L, and DPY30, and plays a key role in histone H3K4 trimethylation, chromatin remodeling, transcriptional activation of target genes, normal biology, and diseases such as MLL-rearranged leukemia.
|
30488017 |
2018 |
Childhood Leukemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The histone H3 lysine 4 (H3K4) presenter WDR5 forms protein complexes with H3K4 methyltransferases MLL1-MLL4 and binding partner proteins including RBBP5, ASH2L, and DPY30, and plays a key role in histone H3K4 trimethylation, chromatin remodeling, transcriptional activation of target genes, normal biology, and diseases such as MLL-rearranged leukemia.
|
30488017 |
2018 |